Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.72 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.72 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468446 | 0.84 | PIK3CD (0.85) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3620904 | 0.83 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2432036 | 0.83 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL393580 | 0.82 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3621995 | 0.82 | PIK3CD (0.75) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL391076 | 0.82 | PIK3CD (0.80) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2466623 | 0.81 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL393460 | 0.81 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL393696 | 0.81 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2469939 | 0.81 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365810-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010065923-A2 | PHOSPHATIDYLINOSITOL-3-KINASE P110 DELTA-TARGETED DRUGS IN THE TREATMENT OF CNS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-06-10 | — | — | WO | disclosed |